Shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) have been assigned an average recommendation of “Hold” from the ten research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $3.50.

Several equities analysts recently weighed in on PRTO shares. Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. Zacks Investment Research lowered shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Finally, HC Wainwright set a $2.00 price target on shares of Proteon Therapeutics and gave the company a “hold” rating in a research report on Wednesday, August 9th.

An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC bought a new position in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics accounts for 0.2% of RA Capital Management LLC’s investment portfolio, making the stock its 22nd biggest position. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics at the end of the most recent reporting period. 47.16% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Proteon Therapeutics, Inc. (PRTO) Given Consensus Rating of “Hold” by Brokerages” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/proteon-therapeutics-inc-prto-given-consensus-rating-of-hold-by-brokerages/1599633.html.

Shares of Proteon Therapeutics (NASDAQ PRTO) traded down 6.98% during mid-day trading on Friday, hitting $2.00. 122,132 shares of the company traded hands. The firm has a 50-day moving average of $1.36 and a 200-day moving average of $1.43. Proteon Therapeutics has a one year low of $1.10 and a one year high of $11.45. The stock’s market capitalization is $35.24 million.

Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.11. On average, equities analysts predict that Proteon Therapeutics will post ($1.52) earnings per share for the current year.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.